论文部分内容阅读
目的比较丙戊酸钠与左乙拉西坦治疗卒中后癫痫的临床疗效和安全性。方法将92例卒中后癫痫的患者按照随机、自愿的原则分为对照组和研究组各46例。所有患者均给予常规治疗,对照组在常规治疗基础上加用左乙拉西坦治疗,研究组在常规治疗基础上加用丙戊酸钠治疗。比较2组患者治疗后的临床效果和用药期间不良反应发生情况。结果丙戊酸钠组患者总有效率93.4%明显高于左乙拉西坦组的78.2%,差异有统计学意义(P<0.05)。2组患者治疗期间均未发生明显不良反应。结论丙戊酸钠治疗卒中后癫痫的临床效果优于左乙拉西坦,且安全性好,值得在临床中推广应用。
Objective To compare the clinical efficacy and safety of sodium valproate and levetiracetam in the treatment of post-stroke epilepsy. Methods Ninety-two patients with epilepsy after stroke were divided into control group and study group according to random and voluntary principle. All patients were given conventional treatment, the control group on the basis of conventional treatment with levetiracetam treatment, the study group on the basis of conventional therapy plus sodium valproate treatment. The clinical effects of two groups of patients after treatment and adverse reactions during the treatment were compared. Results The total effective rate of sodium valproate group 93.4% was significantly higher than that of levetiracetam group 78.2%, the difference was statistically significant (P <0.05). No significant adverse reactions occurred in the two groups during treatment. Conclusion The clinical efficacy of sodium valproate in the treatment of post-stroke epilepsy is superior to that of levetiracetam, and its safety is good. It is worth popularizing in clinic.